Zdrowie i gospodarka · 21.06.2000
Draft Guidance for Industry on Allergic Rhinitis: Clinical Development Programs for Drug Products; Availability
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Allergic Rhinitis: Clinical Development Programs for Drug Products." This draft guidance is intended to assist sponsors of new drug applications (NDA's) in designing development programs for oral and intranasal drug products for the treatment of allergic rhinitis in children and adults.